TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9132323

Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg bid)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Naproxen (500 mg bid)
Number of subjects: 374
Study: 29569943

Group type: EXPERIMENTAL
Intervention: Whole-Body-Vibration (WBV) training on a vibration platform
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nonvibration (NVIB) training on the floor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27430621

Group type: EXPERIMENTAL
Intervention: Coaching plus light therapy and pulsed electromagnetic field therapy for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment with light and pulsed electromagnetic field switched to placebo settings for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Number of subjects: 90

Group type: COMPARATOR
Intervention: Coaching alone for 12 weeks, a course of six sessions, once a fortnight for 50 min
Number of subjects: 90
Study: 24726349

Group type: EXPERIMENTAL
Intervention: n-3-enriched eggs (6 eggs/week)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: nonenriched eggs (6 eggs/week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: egg-free control
Number of subjects: 15
Study: 21755540

Group type: EXPERIMENTAL
Intervention: Asenapine 2 mg BID for 2 days, then 5 mg BID for 2 days, then 10 mg BID thereafter (slow escalation)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID for 4 days, then 10 mg BID thereafter (rapid escalation)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg BID
Number of subjects: 122
Study: 19634922

Group type: EXPERIMENTAL
Intervention: Streptokinase plus enoxaparin
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Fibrin-specific lytic (FSL) plus unfractionated heparin (UFH)
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Fibrin-specific lytic (FSL) plus UFH
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Fibrin-specific lytic (FSL) plus enoxaparin
Number of subjects: 2083
Study: 16757862

Group type: EXPERIMENTAL
Intervention: Artificial neural network (ANN) classifier using [(99m)Tc]TRODAT-1 and SPECT
Number of subjects: 175

Group type: COMPARATOR
Intervention: Conventional ROI analysis of SPECT imaging data
Number of subjects: 175
Study: 14996675

Group type: EXPERIMENTAL
Intervention: Higher tidal volume ventilation (12 mL/kg of predicted weight)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Lower tidal volume ventilation (6 mL/kg of predicted weight)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Ketoconazole, lisofylline, or placebo (by factorial design)
Number of subjects: 902
Study: 11724641

Group type: EXPERIMENTAL
Intervention: Intravenous glutamate infusion (125 mmol x l(‐1) at a rate of 1.5 ml x h(‐1) x kg(‐1) for 1 hour)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo infusion (0.9% NaCl)
Number of subjects: 22
Study: 9259593

Group type: EXPERIMENTAL
Intervention: Liver transplant (LTx) subjects
Number of subjects: 22
Study: 8184807

Group type: EXPERIMENTAL
Intervention: PTCA (n = 25)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No PTCA (n = 19)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Baseline ejection fraction
Number of subjects: 44
Study: 3248354

Group type: EXPERIMENTAL
Intervention: Oxandrolone 2.5 mg/day for 3 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 13
Study: 29695895

Group type: EXPERIMENTAL
Intervention: CBZ+BMT (Carbamazepine 200 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Number of subjects: 185

Group type: COMPARATOR
Intervention: OXC+BMT (Oxcarbazepine 300 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: BMT 18 mg
Number of subjects: 185

Group type: COMPARATOR
Intervention: BMT 12 mg
Number of subjects: 185
Study: 28742880

Group type: EXPERIMENTAL
Intervention: Same-day ART initiation
Number of subjects: 762

Group type: COMPARATOR
Intervention: Standard ART initiation
Number of subjects: 762
Study: 26176993

Group type: EXPERIMENTAL
Intervention: Fitspiration images
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control set of travel images
Number of subjects: 130
Study: 23406850

Group type: EXPERIMENTAL
Intervention: 16F foley catheter traction
Number of subjects: 88

Group type: COMPARATOR
Intervention: 16F foley catheter without traction
Number of subjects: 88
Study: 21710615

Group type: EXPERIMENTAL
Intervention: Antiresorptive treatment (alendronate, clodronate, denosumab, lasofoxifene, zoledronic acid)
Number of subjects: 30118

Group type: EXPERIMENTAL
Intervention: Antiresorptive treatment
Number of subjects: 30118
Study: 19146127

Group type: EXPERIMENTAL
Intervention: In vivo conditions
Number of subjects: 60

Group type: COMPARATOR
Intervention: In vitro conditions with perfused dentin
Number of subjects: 60

Group type: COMPARATOR
Intervention: In vitro conditions without perfused dentin
Number of subjects: 60
Study: 16915526

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (ISI)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion (SLI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study: 14764230

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH) within 12 hours after trauma
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not treated with CVVH)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 29
Study: 10742704

Group type: EXPERIMENTAL
Intervention: Dynamic training on a bicycle ergometer for 30 min three times a week for 3 months, followed by a 3-month home training period.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no change in physical activities).
Number of subjects: 27
Study: 9286519

Group type: COMPARATOR
Intervention: 1% CHX varnish (Cervitec)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of CHX varnish and fluoride varnish (0.1% w/w difluorsilane; Fluor Protector)
Number of subjects: 82
Study: 8420236

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 8
Study: 3607806

Group type: EXPERIMENTAL
Intervention: Frusemide (0.5 mg/kg intravenously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (15 mg intravenously)
Number of subjects: 0
Study: 31778656

Group type: EXPERIMENTAL
Intervention: DSOC-guided biopsy sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: ERCP-guided brushing
Number of subjects: 0
Study: 31241519

Group type: EXPERIMENTAL
Intervention: Wii Fit exergame intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wii video game control
Number of subjects: 20
Study: 28662656

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU once a day for 2 months
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 26260043

Group type: EXPERIMENTAL
Intervention: Diabetes group lifestyle intervention (GLI)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Dietitian referral for medical nutrition therapy (RD)
Number of subjects: 57
Study: 23414196

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Ramipril 10 mg/day
Number of subjects: 138
Study: 21965488

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine (10 mg once per day before surgery, day of surgery, and first day after surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19921355

Group type: EXPERIMENTAL
Intervention: ketamine-propofol (KP)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: ketamine-remifentanil (KR)
Number of subjects: 280

Group type: COMPARATOR
Intervention: ketamine-desflurane (KD)
Number of subjects: 280

Group type: COMPARATOR
Intervention: ketamine-sevoflurane (KS)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: midazolam-propofol (MP)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: midazolam-remifentanil (MR)
Number of subjects: 280

Group type: COMPARATOR
Intervention: midazolam-desflurane (MD)
Number of subjects: 280

Group type: COMPARATOR
Intervention: midazolam-sevoflurane (MS)
Number of subjects: 280
Study: 16953834

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo/Alternative
Number of subjects: 61
Study: 15225171

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: ibuprofen 800 mg three-times daily
Number of subjects: 0
Study: 11291429

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce STD recurrence
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Assessment for sexual abuse in programs focusing on STD/HIV prevention
Number of subjects: 617
Study: 9198491

Group type: EXPERIMENTAL
Intervention: 40 ml Gd-DTPA with three successive acquisitions at fixed intervals (25, 53 and 81 s)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 20 ml Gd-DTPA with individually determined MR acquisition start based on prior evaluation of contrast material transit times
Number of subjects: 50
Study: 8234106

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3302917

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus sisomicin (C/S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piperacillin plus sisomicin
Number of subjects: 60
Study: 31787108

Group type: EXPERIMENTAL
Intervention: Buprenorphine initiated in the community (N=107)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Buprenorphine initiated in prison (N=106)
Number of subjects: 211
Study: 28939185

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (glue) skin adhesive
Number of subjects: 409

Group type: COMPARATOR
Intervention: Antibiotic ointment
Number of subjects: 409

Group type: COMPARATOR
Intervention: Both groups (glue and antibiotic ointment)
Number of subjects: 409
Study: 26438179

Group type: EXPERIMENTAL
Intervention: Propofol + saline
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Propofol + remifentanil (5 ng.mL(‐1))
Number of subjects: 58
Study: 23538911

Group type: EXPERIMENTAL
Intervention: Mindfulness training for 2 weeks
Number of subjects: 0
Study: 21743398

Group type: EXPERIMENTAL
Intervention: Ball attachment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bar attachment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Locator attachment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prostheses
Number of subjects: 36
Study: 19739696

Group type: EXPERIMENTAL
Intervention: Iloperidone (6-12 mg twice daily)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 473
Study: 18447059

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0
Study: 15386823

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 12
Study: 12040346

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 or 60 mg given every 12 hours for 14 days)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice daily for 14 days)
Number of subjects: 1102
Study: 9672165

Group type: EXPERIMENTAL
Intervention: Combination therapy with alpha-interferon and lamivudine for 16 weeks
Number of subjects: 20
Study: 7729237

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 500 mg/day, administered seven to nine hours after awakening (R x 2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Aspirin (ASA) 500 mg/day, administered within two hours of awakening (R x 1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Aspirin (ASA) 500 mg/day, administered within two hours before bedtime (R x 3)
Number of subjects: 55
Study: 2686410

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg every 12 hours intravenously, then oral)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ceftazidime (1 to 2 g intravenously every eight to 12 hours)
Number of subjects: 80
Study: 1105632

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31120118

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (oral factor Xa inhibitor) given at the approved dose for PE for ≥3 months
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (oral factor Xa inhibitor)
Number of subjects: 525
Study: 31507265

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) based intervention on infant immunisation
Number of subjects: 1223
Study: 28099372

Group type: EXPERIMENTAL
Intervention: Simulated learning experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical practicum learning experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final simulated experience
Number of subjects: 0
Study: 25688780

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily for 24 weeks)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1510
Study: 23042475

Group type: EXPERIMENTAL
Intervention: Phonophoresis of 0.4% Dex‐P
Number of subjects: 34

Group type: COMPARATOR
Intervention: Iontophoresis of 0.4% Dex‐P
Number of subjects: 34
Study: 21957245

Group type: EXPERIMENTAL
Intervention: Training in field B followed by training in field A (or washout)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withholding reinforcement for the current motor output
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptation followed by washout or reverse adaptation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lack of reinforcement
Number of subjects: 0
Study: 19100570

Group type: EXPERIMENTAL
Intervention: Interferon with nephrectomy
Number of subjects: 241

Group type: COMPARATOR
Intervention: Interferon without nephrectomy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Performance status 1 vs 0
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: High alkaline phosphatase
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Lung metastasis only
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Early progressive disease within 90 days (in subset surviving at least 90 days)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Performance status (in subset surviving at least 90 days)
Number of subjects: 241
Study: 16287132

Group type: EXPERIMENTAL
Intervention: BNS (nutrition support delivered before treatment)
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: BNS
Number of subjects: 1073

Group type: COMPARATOR
Intervention: TNS (nutrition support delivered during treatment)
Number of subjects: 1073

Group type: COMPARATOR
Intervention: No NS (no nutrition support)
Number of subjects: 1073

Group type: COMPARATOR
Intervention: TNS
Number of subjects: 1073

Group type: COMPARATOR
Intervention: No NS
Number of subjects: 1073
Study: 15230999

Group type: EXPERIMENTAL
Intervention: Milk fortified with Ca
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Milk fortified with Ca and cholecalciferol (5 or 8 microg)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Control group (no milk intervention)
Number of subjects: 757
Study: 11162750

Group type: EXPERIMENTAL
Intervention: adjunctive remacemide hydrochloride 150 mg q.i.d. for 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: adjunctive remacemide hydrochloride
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 9057729

Group type: EXPERIMENTAL
Intervention: IVIg (0.15-0.2 g/kg bodyweight, monthly for 2 years)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 8392903

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 10 micrograms/kg on days 4 to 14
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin starting from 45 mg/m2 every 3 weeks for six courses (Group A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin with GM-CSF priming from day -17 to -7 (Group C)
Number of subjects: 41
Study: 4004191

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (250 mg + 125 mg) three times daily for 7 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cephalexin (250 mg) three times daily for 7 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (for ampicillin-resistant strains)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cephalexin (for ampicillin-resistant strains)
Number of subjects: 80
Study: 30807663

Group type: EXPERIMENTAL
Intervention: GSK561679 350 mg/day for 6 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30029620

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered in the community without an SMS reminder
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered in the community with an SMS reminder
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered in the community with a community health worker reminder
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered at the hospital with an SMS reminder
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine administered at the hospital without an SMS reminder
Number of subjects: 75
Study: 26763023

Group type: EXPERIMENTAL
Intervention: Stroke Self‐Management Program
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Stanford chronic condition self‐management program
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Global disability
Number of subjects: 143
Study: 24985147

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic management targeting HbA1c <6.0% for 4.0 ± 1.2 years
Number of subjects: 4119

Group type: EXPERIMENTAL
Intervention: Pre-transition HbA1c <6.5%
Number of subjects: 4119

Group type: EXPERIMENTAL
Intervention: Lower pre-transition HbA1c levels
Number of subjects: 4119

Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 4119
Study: 22177371

Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg once daily
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study: 16198885

Group type: EXPERIMENTAL
Intervention: Group B (LAVI > 34 mL/m2)
Number of subjects: 104
Study: 11939420

Group type: EXPERIMENTAL
Intervention: Therapist-led group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parent-led group
Number of subjects: 42
Study: 11477904

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of tetramethylpyrazine (TMP) dripped intravenously after anesthesia and 1 mg/kg of TMP infused into oxygenator after CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no TMP treatment)
Number of subjects: 30
Study: 7657041

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every other day
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg on weekends
Number of subjects: 353
Study: 2784977

Group type: EXPERIMENTAL
Intervention: Propofol continuous infusion for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional sedation
Number of subjects: 0
Study: 68331

Group type: EXPERIMENTAL
Intervention: Ethambutol plus isoniazid (E+I)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Rifampicin plus isoniazid (R+I)
Number of subjects: 126
Study: 29188268

Group type: EXPERIMENTAL
Intervention: AQoL-8D
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: FACT-M
Number of subjects: 164
Study: 27498098

Group type: EXPERIMENTAL
Intervention: SDS (specialist depression services)
Number of subjects: 307

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 307
Study: 25299799

Group type: EXPERIMENTAL
Intervention: Iodixanol 270
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iohexol 350
Number of subjects: 80
Study: 23848972

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 24779
Study: 20121889

Group type: EXPERIMENTAL
Intervention: Fish-oil supplement (4 g/day, n = 49)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Olive-oil (placebo, n = 48)
Number of subjects: 97
Study: 17956874

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Intravenous alteplase (fibrinolysis)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Patients transferred to angioplasty
Number of subjects: 1572

Group type: COMPARATOR
Intervention: On-site fibrinolysis
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study: 16832794

Group type: EXPERIMENTAL
Intervention: Community-based intervention of screening for melanoma, including community education program, education program for medical practitioners, and dedicated skin-screening clinics.
Number of subjects: 3355

Group type: EXPERIMENTAL
Intervention: Community-based intervention of screening for melanoma.
Number of subjects: 3355
Study: 12804125

Group type: EXPERIMENTAL
Intervention: Methylphenidate (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10907148

Group type: EXPERIMENTAL
Intervention: Male-exposed couples (observed parental violence by male partner)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Female-exposed couples (observed parental violence by female partner)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Unexposed couples (neither partner observed parental violence)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Unexposed couples
Number of subjects: 71